Repligen Corp (RGEN) stock
Close on Nov 12, 2026Market cap $10.64BP/E –Yield –
Repligen Corp grew revenue 13.8% to $805.61M over the twelve months to Sep 30, 2026. Operating income rose 2185.5% to $18.24M, moving the operating margin from 0.1% to 2.3%. Free cash flow was $106.72M, down 3.0% from a year earlier. At the latest close the market valued the company at $10.64B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $10.64B
- P/E ratio
- –
- Price to sales
- 13.21
- Price to book
- 5.09
- Dividend yield
- –
- Free cash flow yield
- 1.00%
Fundamentals
- Revenue
- $805.61M
- Net income
- -$11.80M
- EPS, diluted
- $0.86
- Free cash flow
- $106.72M
- Book value per share
- $36.98
- Diluted shares
- 57M
Trading
- Next earnings
- Feb 23, 2027 (estimated, before the open)
- Previous close
- $172.62
- Open
- $167.71
- Day's range
- $163.85 – $169.40
- Volume
- 802,979
- Average volume (20 days)
- 1,292,036
- Index membership
- S&P MidCap 400, Russell 1000 (since Jun 2020), Russell 3000
- Beta (5 years)
- 1.47
- 52-week range
- $100.99 – $198.87
- RSI (14 days)
- 42.3
- Volatility (1 year)
- 46.6%
- Relative volume
- 0.67×
- WACC
- 12.3%
Index membership is inferred from the holdings of funds that track each index (IJH, SPMD, IWB, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2010, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | RGEN | S&P 500 | Difference | RGEN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -3.5% | -2.7% | −0.8 pts | ||
| 3 months | +0.5% | -1.7% | +2.2 pts | ||
| Year to date | +1.6% | +11.9% | −10.3 pts | ||
| 1 year | +5.4% | +12.0% | −6.6 pts | ||
| 3 years | +12.8% | +78.2% | −65.3 pts | +4.1% | +21.2% |
| 5 years | -35.6% | +73.2% | −108.8 pts | -8.4% | +11.6% |
| 10 years | +415.7% | +309.6% | +106.1 pts | +17.8% | +15.1% |
Fifteen years at a glance
Fiscal years 2010 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Repligen filed with the SEC as exhibits to Form 8-K or 6-K
- News
- News
- Results
- Update
- Repligen Reports Second Quarter 2026 Financial Results and Updates Full Year 2026 Financial GuidanceResults
- Results
About Repligen
Biological Products, (No Diagnostic Substances)
Repligen Corporation is a life sciences company that develops and supplies bioprocessing technologies and systems used in biological drug manufacturing. Its product offerings include filtration products, chromatography solutions, process analytics products, and proteins. These offerings serve customers across the biopharmaceutical and biotechnology industries, specifically supporting operations within the bioprocessing market.
Company profile, executives and historyRepligen stock: common questions
What is Repligen's stock price?
RGEN closed at $166.52 on Nov 12, 2026, down 3.53% on the day. Over the past 52 weeks it traded between $100.99 and $198.87.
What is Repligen's market cap?
Repligen was worth $10.64B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
How much revenue does Repligen make?
Repligen reported revenue of $805.61M for the twelve months to Sep 30, 2026, up 13.8% from a year earlier.
Does Repligen pay a dividend?
No. Repligen has not paid a cash dividend over the last twelve months.
When does Repligen report earnings next?
Repligen is expected to report Q4 FY2026 results on Feb 23, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has RGEN stock performed over the past year?
Including dividends, RGEN returned +5.4% over the past year, against +12.0% for the S&P 500.
How many RGEN shares are sold short?
7M shares were sold short at the latest FINRA report, 11.10% of the float, or 4.9 days of average trading volume.
Who are Repligen's competitors?
Companies most similar to Repligen by business, industry and size include TECH, QGEN, ADMA, ALVO, TWST.
See a number that looks wrong?